SEARCH

SEARCH BY CITATION

References

  • 1
    Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension Practice Guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24:779785.
  • 2
    Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57:2938.
  • 3
    Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:17771783.
  • 4
    Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens. 2005;19:801807.
  • 5
    Niiranen TJ, Hanninen MR, Johansson J, et al. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension. 2010;55:13461351.
  • 6
    Stergiou GS, Giovas PP, Kollias A, et al. Relationship of home blood pressure with target-organ damage in children and adolescents. Hypertens Res. 2011;34:640644.
  • 7
    Viera AJ, Cohen LW, Mitchell CM, Sloane PD. Hypertensive patients’ use of blood pressure monitors stationed in pharmacies and other locations: a cross-sectional mail survey. BMC Health Serv Res. 2008;8:216.
  • 8
    De la Sierra A, Gorostidi M, Marin R, et al. Evaluation and management of hypertension in Spain. A consensus guide. Med Clin (Barc). 2008;131:104116 (article in Spanish).
  • 9
    Tsuyuki R, Campbell N. 2007 CHEP-CPhA guidelines for the management of hypertension by pharmacists. Can Pharm J. 2007;140:238239.
  • 10
    Sabater-Hernández D, de la Sierra A, Bellver-Monzó O, et al. Action guide for community pharmacist in patients with hypertension and cardiovascular risk. Consensus document (condensed version). Hipertens Riesgo Vasc. 2011;28:169181 (Spanish).
  • 11
    Sabater-Hernández D, Azpilicueta I, Sanchez-Villegas P, et al. Clinical value of blood pressure measurement in the community pharmacy. Pharm World Sci. 2010;32:552558.
  • 12
    Zaninelli A, Parati G, Cricelli C, et al. Office and 24-h ambulatory blood pressure control by treatment in general practice: the ‘Monitoraggio della pressione ARteriosa nella medicina TErritoriale’ study. J Hypertens. 2010;28:910917.
  • 13
    Hanninen MR, Niiranen TJ, Puukka PJ, Jula AM. Comparison of home and ambulatory blood pressure measurement in the diagnosis of masked hypertension. J Hypertens. 2010;28:709714.
  • 14
    Lurbe E, Parati G. Out-of-office blood pressure measurement in children and adolescents. J Hypertens. 2008;26:15361539.
  • 15
    Sabater-Hernández D, de la Sierra A, Sánchez-Villegas P, et al. Magnitude of the white-coat effect in the community pharmacy setting. The MEPAFAR study. Am J Hypertens. 2011;24:887892.
  • 16
    Sendra-Lillo J, Sabater-Hernández D, Sendra-Ortola A, Martinez-Martinez F. Comparison of the white-coat effect in community pharmacy versus the physician’s office: the Palmera study. Blood Press Monit. 2011;16:6266.
  • 17
    Botomino A, Martina B, Ruf D, et al. White coat effect and white coat hypertension in community pharmacy practice. Blood Press Monit. 2005;10:1318.
  • 18
    Topouchian JA, El Assaad MA, Orobinskaia LV, et al. Validation of two automatic devices for self-measurement of blood pressure according to the International Protocol of the European Society of Hypertension: the Omron M6 (HEM-7001-E) and the Omron R7 (HEM 637-IT). Blood Press Monit. 2006;11:165171.
  • 19
    Altunkan S, Ilman N, Kayaturk N, Altunkan E. Validation of the Omron M6 (HEM-7001-E) upper-arm blood pressure measuring device according to the International Protocol in adults and obese adults. Blood Press Monit. 2007;12:219225.
  • 20
    Altunkan S, Iliman N, Altunkan E. Validation of the Omron M6 (HEM-7001-E) upper arm blood pressure measuring device according to the International Protocol in elderly patients. Blood Press Monit. 2008;13:117122.
  • 21
    O’Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23:697701.
  • 22
    Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:21212158.
  • 23
    O’Brien E, Mee F, Atkins N, O’Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society protocol. J Hypertens. 1991;9:573574.
  • 24
    De la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898902.
  • 25
    De la Sierra A, Segura J, Gorostidi M, et al. Diurnal blood pressure variation, risk categories and antihypertensive treatment. Hypertens Res. 2010;33:767771.
  • 26
    Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255268.
  • 27
    Zar JH. Biostatistical Analysis, 4th ed. Saddle River, NJ: Prentice Hall; 1999.
  • 28
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307310.
  • 29
    Fleiss JL. The Design and Analysis of Clinical Experiments, 1st edn. New York, NY: John Wiley & Sons; 1986.
  • 30
    Carrasco JL, Jover L. Statistical approaches to evaluate agreement. Med Clin (Barc). 2004;122(suppl 1):2834 (Spanish).
  • 31
    Altman DG. Practical Statistics for Medical Research. New York, NY: Chapman and Hall; 1991.
  • 32
    Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 33
    Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26:15051526.
  • 34
    Mancia G, Parati G, Bilo G, et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 2007;25:10871094.
  • 35
    Carter BL, Foppe van Mil JW. Comparative effectiveness research: evaluating pharmacist interventions and strategies to improve medication adherence. Am J Hypertens. 2010;23:949955.
  • 36
    Morgado MP, Morgado SR, Mendes LC, et al. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: review and meta-analysis. Am J Health Syst Pharm. 2011;68:241253.
  • 37
    Wentzlaff DM, Carter BL, Ardery G, et al. Sustained blood pressure control following discontinuation of a pharmacist intervention. J Clin Hypertens (Greenwich). 2011;13:431437.
  • 38
    Karwalajtys T, Kaczorowski J, Hutchison B, et al. Blood pressure variability and prevalence of hypertension using automated readings from multiple visits to a pharmacy-based community-wide programme. J Hum Hypertens. 2009;23:585589.
  • 39
    Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement to reduce the white coat response. J Hypertens. 2009;27:280286.